JP2010530846A5 - - Google Patents

Download PDF

Info

Publication number
JP2010530846A5
JP2010530846A5 JP2010510365A JP2010510365A JP2010530846A5 JP 2010530846 A5 JP2010530846 A5 JP 2010530846A5 JP 2010510365 A JP2010510365 A JP 2010510365A JP 2010510365 A JP2010510365 A JP 2010510365A JP 2010530846 A5 JP2010530846 A5 JP 2010530846A5
Authority
JP
Japan
Prior art keywords
peptide
mol
reducing sugar
reducing
histidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010510365A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530846A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/006898 external-priority patent/WO2008150479A2/en
Publication of JP2010530846A publication Critical patent/JP2010530846A/ja
Publication of JP2010530846A5 publication Critical patent/JP2010530846A5/ja
Pending legal-status Critical Current

Links

JP2010510365A 2007-06-01 2008-05-29 高温で安定なペプチド製剤 Pending JP2010530846A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94155607P 2007-06-01 2007-06-01
US96908007P 2007-08-30 2007-08-30
PCT/US2008/006898 WO2008150479A2 (en) 2007-06-01 2008-05-29 High temperature stable peptide formulation

Publications (2)

Publication Number Publication Date
JP2010530846A JP2010530846A (ja) 2010-09-16
JP2010530846A5 true JP2010530846A5 (https=) 2012-07-19

Family

ID=40094334

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010510365A Pending JP2010530846A (ja) 2007-06-01 2008-05-29 高温で安定なペプチド製剤

Country Status (7)

Country Link
US (1) US7879805B2 (https=)
EP (1) EP2150537A4 (https=)
JP (1) JP2010530846A (https=)
AU (1) AU2008260483A1 (https=)
CA (1) CA2687246A1 (https=)
MX (1) MX2009012964A (https=)
WO (1) WO2008150479A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
RU2011126338A (ru) * 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
RU2607526C2 (ru) 2009-11-23 2017-01-10 Кьюбист Фармасьютикалз ЭлЭлСи Липопептидные композиции и родственные способы
WO2011121301A1 (en) 2010-03-31 2011-10-06 Stabilitech Ltd Excipients for stabilising viral particles, polypeptides or biological material
ES2757591T3 (es) 2010-03-31 2020-04-29 Stabilitech Biopharma Ltd Estabilización de partículas virales
CA2795050C (en) * 2010-03-31 2018-05-22 Stabilitech Ltd. Method for preserving alum adjuvants and alum-adjuvanted vaccines
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
US8821865B2 (en) 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations
CN102488889B (zh) * 2011-09-26 2014-01-22 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
CN103315969B (zh) * 2011-09-26 2016-05-18 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
EP2773364A1 (en) * 2011-11-02 2014-09-10 The University of Chicago Stable pharmaceutical formulations of growth factor peptides
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
US20150359864A1 (en) * 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
JP6148487B2 (ja) * 2012-05-31 2017-06-14 久保木 芳徳 チタン−タンパク質複合体の製造方法
EP2698162A1 (en) * 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US10251935B2 (en) * 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
CN106661126B (zh) * 2014-05-28 2021-12-10 诺诺公司 TAT-NR2B9c的氯盐
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2015320545C1 (en) * 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
CN109528761A (zh) * 2018-12-20 2019-03-29 江西润泽药业有限公司 制备钠钾钙镁葡萄糖注射液的方法
EP4117625A1 (en) 2020-03-12 2023-01-18 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
CN115397454A (zh) * 2020-03-31 2022-11-25 立美基股份有限公司 通过辐照对自组装肽进行灭菌
KR102869156B1 (ko) * 2021-03-29 2025-10-15 (주)아모레퍼시픽 콜라겐 펩티드 안정화용 조성물 및 이를 포함하는 식품

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
AUPO871997A0 (en) * 1997-08-25 1997-09-18 Csl Limited Dried biologically or therapeutically active preparations
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
JP2003055257A (ja) * 2001-08-10 2003-02-26 Nihon Pharmaceutical Co Ltd 安定な血液凝固第xiii因子製剤
EP1503767A2 (en) * 2002-02-08 2005-02-09 ACOLOGIX, Inc. Compositions and methods for treatment of vitamin d deficiency
EP1556091A1 (en) * 2002-10-04 2005-07-27 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
CA2576519C (en) * 2004-08-17 2013-05-21 Regeneron Pharmaceuticals, Inc. Il-1 antagonist formulations

Similar Documents

Publication Publication Date Title
JP2010530846A5 (https=)
JP2007262090A5 (https=)
JP2011506530A5 (https=)
JP2011088897A5 (https=)
JP2010534684A5 (https=)
TWD123746S1 (zh) 繃帶
JP2013510216A5 (https=)
JP2010522208A5 (https=)
JP2013507408A5 (https=)
JP2009017880A5 (https=)
JP2011528897A5 (https=)
JP2011526526A5 (https=)
JP2011181765A5 (https=)
JP2012531980A5 (https=)
WO2008069911A3 (en) Dual composition with warming and analgesic effects
JP2012500946A5 (https=)
JP2006342148A5 (https=)
JP2009242695A5 (https=)
JP2010030903A5 (https=)
WO2010098625A3 (ko) 약제학적 제제
Yip Eco-city: From Concept to Implementation-Case Studies in Shanghai Dongtan and Beijing Changxindian
JP2008143899A5 (https=)
JP2007119348A5 (https=)
Levine Today is a new day
申美花 The Historic Study of Morphology in Korean